MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma
RAS proto-oncogene specifically plays a crucial role in the transduction of growth-promoting signals and cellular proliferation (6). [...]activation of this MAPK signaling pathway is one of the most significant with respect to cell differentiation which subsequently leads to the desired biotic event...
Gespeichert in:
| Veröffentlicht in: | Future medicinal chemistry 2019-04, Vol.11 (8), p.793-795 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 795 |
|---|---|
| container_issue | 8 |
| container_start_page | 793 |
| container_title | Future medicinal chemistry |
| container_volume | 11 |
| creator | Pradhan, Rajesh Singhvi, Gautam Dubey, Sunil Kumar Gupta, Gaurav Dua, Kamal |
| description | RAS proto-oncogene specifically plays a crucial role in the transduction of growth-promoting signals and cellular proliferation (6). [...]activation of this MAPK signaling pathway is one of the most significant with respect to cell differentiation which subsequently leads to the desired biotic events. [...]atypical cellular activity (such as cell proliferation, angiogenesis, invasion and metastasis) occur innon-small lung cells. [...]another second-generation MEK inhibitor (PD0325901) has entered clinical trials; and thankfully, it has displayed better therapeutic activity and pharmaceutical properties than PD184352 (11,16). Based on this and because of the documented activation of the MEK pathway in NSCLC, MEK is still considered as an effective objective for NSCLC. [...]LGX818 is a BRAF inhibitor, which inhibits the proliferation of the malignancy cell line by blocking multi-signaling pathways such as ERK phosphorylation, RAF kinase inhibitors and mTOR inhibitors. |
| doi_str_mv | 10.4155/fmc-2018-0468 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2210954909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2210954909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-30269f712b5482e9e58a0f9b1d5abc7056ef664b1c63a725312f9b53108f93d63</originalsourceid><addsrcrecordid>eNp9kU1rFTEUhoMottQu3UrAjZvUfH-4K6VqscVCdR0yuSftlJnJNckg_ffmcmsXgs3m5HCevBzyIPSW0RPJlPqY5kg4ZZZQqe0LdMiM0sQ6bl4-3Zk7QMe13tN-BLdOq9foQFDnJOXyEN1cnV5_w9vQ7n6Hh0844G1usLQxTLiFcgsNp1xwuwPcCoQ29xnOCS95IXUO00QiTBOe1uUWx1DiuOQ5vEGvUpgqHD_WI_Tz8_mPs6_k8vuXi7PTSxKlsI0IyrVLhvFBScvBgbKBJjewjQpDNFRpSFrLgUUtguFKMN6nvVCbnNhocYQ-7HO3Jf9aoTY_j3W3T1ggr9VzzqhT0lHX0ff_oPd5LUvfznPFFDXOKPUsJawymkljO0X2VCy51gLJb8s4h_LgGfU7Lb5r8Tstfqel8-8eU9dhhs0T_VdCB9weSGtbC9Q4whLB77v-YuzfCv8J_wMphpiu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2385761478</pqid></control><display><type>article</type><title>MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma</title><source>MEDLINE</source><source>PubMed Central</source><creator>Pradhan, Rajesh ; Singhvi, Gautam ; Dubey, Sunil Kumar ; Gupta, Gaurav ; Dua, Kamal</creator><creatorcontrib>Pradhan, Rajesh ; Singhvi, Gautam ; Dubey, Sunil Kumar ; Gupta, Gaurav ; Dua, Kamal</creatorcontrib><description>RAS proto-oncogene specifically plays a crucial role in the transduction of growth-promoting signals and cellular proliferation (6). [...]activation of this MAPK signaling pathway is one of the most significant with respect to cell differentiation which subsequently leads to the desired biotic events. [...]atypical cellular activity (such as cell proliferation, angiogenesis, invasion and metastasis) occur innon-small lung cells. [...]another second-generation MEK inhibitor (PD0325901) has entered clinical trials; and thankfully, it has displayed better therapeutic activity and pharmaceutical properties than PD184352 (11,16). Based on this and because of the documented activation of the MEK pathway in NSCLC, MEK is still considered as an effective objective for NSCLC. [...]LGX818 is a BRAF inhibitor, which inhibits the proliferation of the malignancy cell line by blocking multi-signaling pathways such as ERK phosphorylation, RAF kinase inhibitors and mTOR inhibitors.</description><identifier>ISSN: 1756-8919</identifier><identifier>EISSN: 1756-8927</identifier><identifier>DOI: 10.4155/fmc-2018-0468</identifier><identifier>PMID: 30994024</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Angiogenesis ; Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Apoptosis ; cancer ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - metabolism ; Cell differentiation ; Cell growth ; Cell proliferation ; Clinical trials ; EGFR ; Epidermal growth factor ; epidermal growth factor receptor ; ErbB Receptors - metabolism ; Extracellular signal-regulated kinase ; Gene expression ; Humans ; Kinases ; Ligands ; Lung cancer ; Lung carcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Malignancy ; MAP kinase ; MAP Kinase Signaling System - drug effects ; MAPK ; MAPK pathway ; Medical prognosis ; MEK inhibitors ; Metastases ; Metastasis ; Molecular Targeted Therapy ; Mutation ; Non-small cell lung carcinoma ; Pathogenesis ; Pharmacy ; Phosphorylation ; Proteins ; Raf protein ; RAS ; Science ; Signal transduction ; TOR protein ; Tumors</subject><ispartof>Future medicinal chemistry, 2019-04, Vol.11 (8), p.793-795</ispartof><rights>2019 Newlands Press</rights><rights>Copyright Newlands Press Apr 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-30269f712b5482e9e58a0f9b1d5abc7056ef664b1c63a725312f9b53108f93d63</citedby><cites>FETCH-LOGICAL-c438t-30269f712b5482e9e58a0f9b1d5abc7056ef664b1c63a725312f9b53108f93d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30994024$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pradhan, Rajesh</creatorcontrib><creatorcontrib>Singhvi, Gautam</creatorcontrib><creatorcontrib>Dubey, Sunil Kumar</creatorcontrib><creatorcontrib>Gupta, Gaurav</creatorcontrib><creatorcontrib>Dua, Kamal</creatorcontrib><title>MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma</title><title>Future medicinal chemistry</title><addtitle>Future Med Chem</addtitle><description>RAS proto-oncogene specifically plays a crucial role in the transduction of growth-promoting signals and cellular proliferation (6). [...]activation of this MAPK signaling pathway is one of the most significant with respect to cell differentiation which subsequently leads to the desired biotic events. [...]atypical cellular activity (such as cell proliferation, angiogenesis, invasion and metastasis) occur innon-small lung cells. [...]another second-generation MEK inhibitor (PD0325901) has entered clinical trials; and thankfully, it has displayed better therapeutic activity and pharmaceutical properties than PD184352 (11,16). Based on this and because of the documented activation of the MEK pathway in NSCLC, MEK is still considered as an effective objective for NSCLC. [...]LGX818 is a BRAF inhibitor, which inhibits the proliferation of the malignancy cell line by blocking multi-signaling pathways such as ERK phosphorylation, RAF kinase inhibitors and mTOR inhibitors.</description><subject>Angiogenesis</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Cell differentiation</subject><subject>Cell growth</subject><subject>Cell proliferation</subject><subject>Clinical trials</subject><subject>EGFR</subject><subject>Epidermal growth factor</subject><subject>epidermal growth factor receptor</subject><subject>ErbB Receptors - metabolism</subject><subject>Extracellular signal-regulated kinase</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Malignancy</subject><subject>MAP kinase</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>MAPK</subject><subject>MAPK pathway</subject><subject>Medical prognosis</subject><subject>MEK inhibitors</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Pathogenesis</subject><subject>Pharmacy</subject><subject>Phosphorylation</subject><subject>Proteins</subject><subject>Raf protein</subject><subject>RAS</subject><subject>Science</subject><subject>Signal transduction</subject><subject>TOR protein</subject><subject>Tumors</subject><issn>1756-8919</issn><issn>1756-8927</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1rFTEUhoMottQu3UrAjZvUfH-4K6VqscVCdR0yuSftlJnJNckg_ffmcmsXgs3m5HCevBzyIPSW0RPJlPqY5kg4ZZZQqe0LdMiM0sQ6bl4-3Zk7QMe13tN-BLdOq9foQFDnJOXyEN1cnV5_w9vQ7n6Hh0844G1usLQxTLiFcgsNp1xwuwPcCoQ29xnOCS95IXUO00QiTBOe1uUWx1DiuOQ5vEGvUpgqHD_WI_Tz8_mPs6_k8vuXi7PTSxKlsI0IyrVLhvFBScvBgbKBJjewjQpDNFRpSFrLgUUtguFKMN6nvVCbnNhocYQ-7HO3Jf9aoTY_j3W3T1ggr9VzzqhT0lHX0ff_oPd5LUvfznPFFDXOKPUsJawymkljO0X2VCy51gLJb8s4h_LgGfU7Lb5r8Tstfqel8-8eU9dhhs0T_VdCB9weSGtbC9Q4whLB77v-YuzfCv8J_wMphpiu</recordid><startdate>20190401</startdate><startdate>20190401</startdate><enddate>20190401</enddate><enddate>20190401</enddate><creator>Pradhan, Rajesh</creator><creator>Singhvi, Gautam</creator><creator>Dubey, Sunil Kumar</creator><creator>Gupta, Gaurav</creator><creator>Dua, Kamal</creator><general>Future Science Ltd</general><general>Newlands Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190401</creationdate><title>MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma</title><author>Pradhan, Rajesh ; Singhvi, Gautam ; Dubey, Sunil Kumar ; Gupta, Gaurav ; Dua, Kamal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-30269f712b5482e9e58a0f9b1d5abc7056ef664b1c63a725312f9b53108f93d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Angiogenesis</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Cell differentiation</topic><topic>Cell growth</topic><topic>Cell proliferation</topic><topic>Clinical trials</topic><topic>EGFR</topic><topic>Epidermal growth factor</topic><topic>epidermal growth factor receptor</topic><topic>ErbB Receptors - metabolism</topic><topic>Extracellular signal-regulated kinase</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Malignancy</topic><topic>MAP kinase</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>MAPK</topic><topic>MAPK pathway</topic><topic>Medical prognosis</topic><topic>MEK inhibitors</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Pathogenesis</topic><topic>Pharmacy</topic><topic>Phosphorylation</topic><topic>Proteins</topic><topic>Raf protein</topic><topic>RAS</topic><topic>Science</topic><topic>Signal transduction</topic><topic>TOR protein</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pradhan, Rajesh</creatorcontrib><creatorcontrib>Singhvi, Gautam</creatorcontrib><creatorcontrib>Dubey, Sunil Kumar</creatorcontrib><creatorcontrib>Gupta, Gaurav</creatorcontrib><creatorcontrib>Dua, Kamal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pradhan, Rajesh</au><au>Singhvi, Gautam</au><au>Dubey, Sunil Kumar</au><au>Gupta, Gaurav</au><au>Dua, Kamal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma</atitle><jtitle>Future medicinal chemistry</jtitle><addtitle>Future Med Chem</addtitle><date>2019-04-01</date><date>2019-04-01</date><risdate>2019</risdate><risdate>2019</risdate><volume>11</volume><issue>8</issue><spage>793</spage><epage>795</epage><pages>793-795</pages><issn>1756-8919</issn><eissn>1756-8927</eissn><abstract>RAS proto-oncogene specifically plays a crucial role in the transduction of growth-promoting signals and cellular proliferation (6). [...]activation of this MAPK signaling pathway is one of the most significant with respect to cell differentiation which subsequently leads to the desired biotic events. [...]atypical cellular activity (such as cell proliferation, angiogenesis, invasion and metastasis) occur innon-small lung cells. [...]another second-generation MEK inhibitor (PD0325901) has entered clinical trials; and thankfully, it has displayed better therapeutic activity and pharmaceutical properties than PD184352 (11,16). Based on this and because of the documented activation of the MEK pathway in NSCLC, MEK is still considered as an effective objective for NSCLC. [...]LGX818 is a BRAF inhibitor, which inhibits the proliferation of the malignancy cell line by blocking multi-signaling pathways such as ERK phosphorylation, RAF kinase inhibitors and mTOR inhibitors.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>30994024</pmid><doi>10.4155/fmc-2018-0468</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-8919 |
| ispartof | Future medicinal chemistry, 2019-04, Vol.11 (8), p.793-795 |
| issn | 1756-8919 1756-8927 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2210954909 |
| source | MEDLINE; PubMed Central |
| subjects | Angiogenesis Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Cell differentiation Cell growth Cell proliferation Clinical trials EGFR Epidermal growth factor epidermal growth factor receptor ErbB Receptors - metabolism Extracellular signal-regulated kinase Gene expression Humans Kinases Ligands Lung cancer Lung carcinoma Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Malignancy MAP kinase MAP Kinase Signaling System - drug effects MAPK MAPK pathway Medical prognosis MEK inhibitors Metastases Metastasis Molecular Targeted Therapy Mutation Non-small cell lung carcinoma Pathogenesis Pharmacy Phosphorylation Proteins Raf protein RAS Science Signal transduction TOR protein Tumors |
| title | MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A48%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAPK%20pathway:%20a%20potential%20target%20for%20the%20treatment%20of%20non-small-cell%20lung%20carcinoma&rft.jtitle=Future%20medicinal%20chemistry&rft.au=Pradhan,%20Rajesh&rft.date=2019-04-01&rft.volume=11&rft.issue=8&rft.spage=793&rft.epage=795&rft.pages=793-795&rft.issn=1756-8919&rft.eissn=1756-8927&rft_id=info:doi/10.4155/fmc-2018-0468&rft_dat=%3Cproquest_cross%3E2210954909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2385761478&rft_id=info:pmid/30994024&rfr_iscdi=true |